Prosthetic capsular devices, systems, and methods

Information

  • Patent Grant
  • 11607307
  • Patent Number
    11,607,307
  • Date Filed
    Thursday, December 2, 2021
    2 years ago
  • Date Issued
    Tuesday, March 21, 2023
    a year ago
Abstract
The present invention relates to a prosthetic capsular bag and method for inserting the same. The prosthetic capsular bag helps to maintain the volume of the natural capsular bag, thereby stabilizing the effective lens position of an IOL so that refractive outcomes may be improved with cataract surgery. The prosthetic capsular bag further provides an integrated refractive surface, providing a means for experimentally determining an effective lens position prior to inserting an IOL.
Description
BACKGROUND
(a) Technical Field

The present invention relates to a prosthetic capsular bag and method for inserting the same.


(b) Description of the Related Art

Cataract surgery is one of the most successfully and most frequently performed surgical procedures in the US. Each year, millions of people achieve a dramatic improvement in their visual function thanks to this procedure. With the increasing proportion of the US population reaching their retirement years, there is expected to be a doubling of the demand for cataract surgery over the next twenty years from 3.3 million to over 6 million annually. This increased demand will require more ophthalmologists to be trained to perform cataract surgery as well as each trained ophthalmologist to perform more cataract surgeries each year.


In addition to the increase in demand for cataract surgery, there have been many technological advances that have increased patient expectations and requirements for the surgery. The procedure takes a short amount of time to perform, and patients expect quick recovery of visual function. Patients are also asking their ophthalmologist to give them restoration of more youthful vision without glasses through the use of multifocal lenses, presbyopia correcting lenses, toric lenses, and monovision to name a few. The use of these lenses requires perfect technique, perfect preoperative measurements, and a dose of good fortune to ensure patient satisfaction. In fact, as many as 20-50% of patients will typically require glasses or follow up refractive surgical enhancements to achieve their desired refractive endpoint. The reason for this high amount of refractive unpredictability comes from the final resting position of the lens implant within the eye. This is mathematically expressed as the effective lens position (“ELP”), and can be quite variable and unpredictable in the current state of cataract surgery. Recently, hundreds of millions of dollars have been invested into developing highly sophisticated femtosecond laser systems that will be able to more precisely create the cataract incisions with the stated goal of lessoning the variability of the ELP and thus aiding in better refractive outcomes. However, as good as the laser is, it does not account for the major problem plaguing the variability of the ELP, which is the volumetric difference between the cataract, natural capsular bag and intraocular lens implant, or IOL.


SUMMARY

The present invention relates to a prosthetic capsular bag and method for inserting the same. The prosthetic capsular bag addresses the above mentioned problem by helping to maintain the volume of the natural capsular bag, thereby stabilizing the effective lens position of the IOL and improving refractive outcomes with cataract surgery. The prosthetic capsular bag further provides an integrated refractive surface, providing a means for experimentally determining an effective lens position prior to inserting an IOL. Herein, the prosthetic capsular bag of the present invention is referred to as a Perfect Prosthetic Lenticular Capsule or “PPL-C.”


In one embodiment, the present invention is a prosthetic capsular bag for insertion into an eye, the prosthetic capsular bag comprising an anterior surface including an opening, and a posterior surface, wherein at least a portion of the posterior surface is a refractive surface. In this embodiment, the prosthetic capsular bag is adapted to contain an intraocular lens.


In a further embodiment, the present invention is a prosthetic capsular bag for insertion into an eye, the prosthetic capsular bag having a generally discoid shape including a posterior surface, an anterior surface including an opening, and a flange extending radially from the opening.


In another embodiment, the present invention is a prosthetic barrier for separating an anterior segment and poster segment in an eye, the barrier having a generally discoid shape including a posterior surface, an anterior surface including an opening, and an exterior contour flange extending radially from the opening.


In a further embodiment, the present invention is a method for inserting and positioning an intraocular lens into a patient's eye comprising: (a) inserting a prosthetic capsular bag into the patient's eye, the prosthetic capsular bag including an anterior surface, the anterior surface having an opening, and a posterior surface, wherein at least a portion of the posterior surface is a refractive surface; (b) determining the position of the refractive surface; (c) selecting an intraocular lens based on the determined position of the refractive surface; and (d) inserting the intraocular lens into the prosthetic capsular bag.





BRIEF DESCRIPTION OF THE DRAWINGS

A better understanding of the present invention will be had upon reference to the following description in conjunction with the accompanying drawings, wherein:



FIG. 1 depicts a cross-sectional side view of an eye including a first embodiment of a PPL-C containing an IOL.



FIG. 2 depicts a side elevation view of the first embodiment of the PPL-C;



FIG. 3 depicts an anterior plan view of the first embodiment of the PPL-C;



FIG. 4 is a flowchart of a method for inserting and positioning an intraocular lens into a patient's eye;



FIG. 5 depicts a cross-sectional side view of an eye including a second embodiment of a PPL-C containing an IOL.



FIG. 6 depicts a side elevation view of the second embodiment of the PPL-C; and



FIG. 7 depicts an anterior plan view of the second embodiment of the PPL-C.





DETAILED DESCRIPTION

With reference to FIGS. 1-3, the PPL-C 10 of the instant invention is shown approximating the size and shape and volume of a natural human lens. Its dimensions would be variable, so that physicians may order an implant that most closely matches the lens of the eye 12 being operated on. The human lens varies in thickness from approximately 3.5 mm to 5.5 mm. A natural lens tends to be thicker in more hyperopic eyes and thinner in more myopic eyes. Also, the lens thickens over time and increased age is associated with a thicker lens on average. The diameter of the human lens is approximately 9 mm. Therefore, in one embodiment, the PPL-C 10 would be a substantially discoid shape of approximately 4.5 mm in thickness by 9 mm in diameter. For purposes of clarity, the thickness of the PPL-C 10 is the distance between the anterior surface 14 and posterior surface 16 of the PPL-C 10 along the visual axis 15. The anterior surface 14 contains a circular opening 18 approximately 6 mm in diameter, with an exterior contour, such as, for example, a 1 mm flange 20, surrounding and extending radially from the opening 18. The flange 20 would further assist in stabilization and centration of the PPL-C 10 by extending into and fitting within the ciliary sulcus 22. This size of PPL-C 10 would function to fit precisely within the capsulorhexis created by a femtosecond laser.


At least a portion of the inner face 17 of the posterior surface 16 of the PPL-C 10 would be made of a refractive surface so that a pseudophakic refraction could be performed intraoperatively with a known lens already inside the eye, e.g. the posterior refractive surface 19. In a preferred embodiment, as shown in FIGS. 1-3, substantially the entire inner face 17 would be made of a low power refractive surface (for example +1D). While the posterior refractive surface 19 is generally discussed in terms of a +1D surface, it may be made of any and all lens powers and designs that are currently known in the art of intraocular lenses. This includes, but is not limited to: spherical, aspheric, wavefront, convex, concave, multifocal (diffractive, refractive, zonal), toric, accommodative, UV filtering, and diffractive chromatic aberration reducing lenses, and optical powers ranging from +30 to −30 diopters.


The PPL-C 10 is adapted to be implanted within the eye and is preferably made of a biologically-compatible material that would be inert inside the eye. It is preferably deformable so as to be folded and inserted via an injection system through a corneal incision ranging between about 0.1 mm and 10 mm, preferably between about 1.5 mm and 3 mm. The size of the corneal incision varies based on several factors, including the volume of the PPL-C 10, its plasticity, and the volume of the injection cartridge through which the PPL-C 10 will be delivered. The capsulorhexis must be about equal to or less than the dilated diameter of the patient's iris as the opacity of the iris forms a natural barrier for the capsulorhexis created by a femtosecond laser. A capsulorhexis created manually is typically of the same size, as direct visualization of the rhexis boundary is advisable throughout the creation process. The capsulorhexis ranges between about 3 mm and 8 mm, preferably between about 4 mm and 7 mm. During implantation, the folded PPL-C 10 passes through the corneal incision, through the capsulorhexis, and into the patient's natural capsular bag 24. The PPL-C 10 preferably also possesses sufficient elasticity to resume its pre-folded shape once positioned inside the eye. Current intraocular lenses are made of various materials including silicone, collamer, and acrylic that have these capabilities. In preferred embodiments, the material used for the PPL-C 10 is a biologically-compatible, optically clear material similar or identical to those used in foldable intraocular lenses.


The PPL-C 10 would preferably be inserted into the patient's eye 12 through the use of an injection system. The injection system would allow the PPL-C 10 to be automatically folded into a smaller shape as it was advanced so as to allow it to fit through an incision much smaller than the diameter of the unfolded PPL-C 10. The inventor believes that injection systems already developed through which IOLs are injected into the eye, which comprise a cylindrical cartridge and an advancement rod on a screw type advancement system or plunger advancement system, would be suitable for use with the PPL-C 10.


The PPL-C 10 is preferably inserted into a patient's eye 12 with the use of a laser. A femtosecond laser would be used to create the capsulorhexis, likely after the same device was used to make the other incisions including the main wound, the paracentesis and any corneal or limbal relaxing incisions as necessary. The cataract, i.e., the patient's natural lens, would then be removed using techniques known in the art. The residual cortex would be removed using technique known in the art, such as via inspiration/aspiration. An aphakic refraction would be completed using an intraocular refracting device such as, for example, the Wavetec ORA system. An IOL calculation would be performed using an algorithm such as, for example, the Mackool algorithm. Then, the patient's natural capsular bag 24 and anterior segment 26 would be filled with viscoelastic material, and the PPL-C 10 would be loaded into the injection device. It would be folded into a small tubular shape and injected into the natural capsular bag 24. The viscoelastic material would be removed from behind the PPL-C, and from the anterior segment 26. A pseudophakic refraction would be done with a system similar to a standard auto-refractor, or the intraoperative Wavetec ORA system. This calculation would need to be done using approved protocols.


An example refraction using an approved protocol, and accompanying background information, is discussed herein. Current state of the art requires multiple independent variables to be measured so that the dependent variable of effective lens position can be estimated. These independent variables in the Holladay 2 formula (one of the most popular modern formulas) are in decreasing order of importance include: axial length, average keratometric power, horizontal white to white, refraction, anterior segment depth, lens thickness, and age. These variables are then used to estimate the ELP. However, this is simply an estimation or prediction. If this prediction is incorrect, the post-operative refractive outcome will be compromised. Therefore, emphasis should be placed on the ability to determine the ELP rather than estimating it. The PPL-C 10 will help determine the ELP in two different ways, as described in the procedure below.



FIG. 4 is a flowchart depicting a method for inserting and positioning an intraocular lens into a patient's eye. First, the lens thickness of a patient's natural lens is determined pre-operatively using known techniques. Next, a PPL-C 10 of similar thickness will be chosen for implantation. The goal will be to select a PPL-C 10 sized such that the inner face 17 of the PPL-C 10 at the same location as the posterior surface of the patient's natural lens. When an IOL 28 is inserted within the PPL-C adjacent to the inner face 17 and centered within the PPL-C 10, that IOL 28 will be positioned in substantially the identical location previously occupied by the patient's natural lens.


A femtosecond laser is used to create the main wound, the paracentesis and any corneal or limbal relaxing incisions as necessary, and the capsulorhexis. The patient's natural lens is then removed using techniques known in the art. The residual cortex is removed using techniques known in the art, such as via inspiration/aspiration. Then, the patient's natural capsular bag 24 and anterior segment 26 are filled with viscoelastic material, and the PPL-C 10 inserted into the natural capsular bag 24. The viscoelastic material is then removed from behind the PPL-C, and from the anterior segment 26 in preparation for performing a pseudophakic refraction.


By being able to identify and control the position of the IOL 28, choosing an IOL 28 is no longer dependent upon the 7 variables for ELP. Rather, via theoretical vergence formulas, the exact IOL 28 needed to provide a desired refractive outcome can be specifically calculated with keratometric power, effective lens position and axial length. The current weakness of the formulas in place is due to the inability to accurately predict ELP. To confirm the pre-operative theoretical calculation is correct, a refraction is performed in the operating room once the PPL-C 10 is implanted in the patient's eye via a Wavetec ORA system, retinoscopy or by other known methods. The refraction will technically be a pseudophakic refraction as the posterior refractive surface 19 of the PPL-C 10 will have a refractive power, such as, for example, +1 diopter.


A method of determining the correct intraocular power for a piggyback lens is calculated by first determining the power of the IOL 28 to be implanted using the following equation:






IOLe
=


1336


1336


1000


1000
PreRx

-
V


+
Ko


-
ELPo


-

1336


1336


1000


1000
DPostRx

-
V


+
Ko


-
ELPo








ELP o=effective lens position.


K o=net corneal power.


IOL e=IOL power.


V=vertex distance.


PreRx=pre-op refraction. (Also can represent the intra-operative refraction after PPL-C has been placed)


DPostRx=desired post-op refraction.


The Effective Lens Position (ELPo) is the distance from the secondary principal plane of the cornea to the principal plane of the thin-IOL equivalent. The keratometric power of the cornea (Kk) is converted to the net optical power of the cornea (Ko) as follows: Ko=Kk*0.98765431. For example, if the Kk is 44.50 D, Ko=44.50 D*0.98765431=43.95 D. The net optical power of the cornea (Ko) would then be 43.95 D.


By comparing pre-operative theoretical IOL calculations with the aphakic refraction, the PPL-C refraction, and the post-IOL implantation refraction, surgeons can greatly improve the accuracy of their post-operative refractive outcomes.


Once the appropriate IOL 28 is selected, the PPL-C 10 and anterior segment 26 are refilled with viscoelastic material and, based on the residual refractive error, the appropriate IOL 28 is selected and inserted into the PPL-C 10. The viscoelastic material is then removed from the eye, and the wounds closed through standard methods of hydration or suturing. A final confirmatory refraction would be completed, taking great effort to ensure normal intraocular pressure, as this can affect the position of the PPL-C 10 and IOL 28 inside the eye. If there were found to be a significant error at this point, the surgeon would still have the luxury of removing the implanted IOL and replacing it with one of a more desirable refractive power, without risking damage to the fragile natural capsular bag 24, due to the protective nature of having the IOL 28 contained within the PPL-C 10.


The PPL-C 10 provides an enhanced ability to achieve desired refractive targets, with a side benefit of increased safety. This implant will provide these advantages in several ways.


First, the PPL-C 10 provides centration of the IOL 28 along the visual axis 15. A femtosecond cataract laser system has the ability to center the capsulorhexis around the visual axis 15 of the patient rather than the optical center of the cataract. The capsulorhexis is ultimately what will center the PPL-C 10 as this is the opening through which the PPL-C 10 will be inserted. The capsulorhexis is essentially juxtaposed at the center of the PPL-C 10, centering the PPL-C 10 and being stabilized via the flange 20 extending into and fitting within the ciliary sulcus 22. The flange 20 mechanically retains the PPL-C 10 centered on the patient's visual axis 15 and prevents future movement or migration of the PPL-C 10.


Centration of the IOL 28 on the visual axis 15 is extremely important to the visual function of the IOL 28 and the benefit the patient receives. Aspheric lenses have made decentration more tolerable, however centration is absolutely vital to the best visual performance of multifocal intraocular lenses. Decentration of less than 1 mm can cause significant morbidity, so much so that surgical intervention including laser pupiloplasty, IOL repositioning and IOL exchange are often needed. The PPL-C 10 is centered along the visual axis 15 via the capsulorhexis. An IOL 28 commonly includes haptics 30 which can engage opposed interior surfaces within the PPL-C 10 to maintain the centered position of the IOL 28. The outer diameter of the IOL 28, when unfolded and including the haptics 30, is substantially equal to the inner diameter of the PPL-C 10. Therefore, the IOL 28 will be in physical contact with the peripheral internal surface of the PPL-C 10, which maintains the centered position of the IOL 28 within the PPL-C 10 and also within the visual axis 15.


Second, the PPL-C 10 provides a prosthetic barrier between the anterior segment 26 and posterior segment 32 of the eye in the case of inadvertent rupture of the posterior surface of the natural capsular bag 24, or after planned YAG laser posterior capsulotomy. Despite the overall success of cataract surgery, there is still about a 2% surgical complication rate utilizing modern techniques, although this varies among individual surgeons. Residents in ophthalmology training programs have historically had complication rates around 4-7%. Most complications from cataract surgery are caused by inadvertent rupture of the natural capsular bag 24 which houses the cataract. The natural capsular bag 24 also provides an important anatomical barrier within the eye. It divides the anterior segment 26 from the posterior segment 32. The posterior segment 32 contains the vitreous body, retina, optic nerve and the central retinal artery and vein. A violation of the integrity of the barrier provided by the natural capsular bag 24 allows fluid communication between the anterior and posterior segments 26, 32, and potentially the ocular surface. Vitreous may then flow out of the posterior segment 32 according to pressure gradients, flowing from high pressure toward low pressure. This typically causes vitreous to flow directly to the surgical incision site. Vitreous can prevent wound healing if it shifts to the surgical incision site, and more significantly can provide a conduit for microbial infections to proceed directly to the posterior segment 32. In addition to the problems caused by vitreous, a break or tear in the natural capsular bag 24 can prevent the stable implantation of an IOL within the posterior segment 32. Alternatively, surgeons can place an IOL 28 in the ciliary sulcus 22 or the anterior chamber, although each of these has their own potential complications associated with them. Therefore it is of utmost importance to keep the natural capsular bag 24 intact as there are currently no methods to consistently reestablish the integrity of the natural capsular bag 24 once it has been compromised. Should the natural capsular bag 24 be compromised, the PPL-C 10 may serve as a prosthetic barrier between the anterior segment 26 and posterior segment 32.


About 30% of all implanted intraocular lenses will develop visually significant posterior capsular opacification. If this develops, a YAG laser is used to create an opening in the posterior surface of the natural capsular bag 24 to remove this opaque membrane. However, once the hole in the natural capsular bag 24 is created, the barrier between the vitreous and the anterior segment 26 has been lost. Thus, if the lens needs to be removed after a YAG laser posterior capsulotomy has been performed, it makes the chances for serious complications rise dramatically. However, if a PPL-C 10 is placed in the natural capsular bag 24 and a YAG laser posterior capsulotomy has been performed, there is still an adequate barrier for the vitreous in place. In addition, the haptics 30 which hold the IOL 28 in place inside the PPL-C 10 are not prone to scar formation, thus making future lens removal much easier and decreasing the risk for complications during IOL exchange.


Third, the PPL-C 10 limits the chronic capsular opacification that takes place in the natural capsular bag 24 and can cause refractive shifts due to ELP change, anterior capsular phimosis, and visually significant posterior capsular opacification. After cataract surgery has been performed, the natural capsular bag 24 undergoes chronic changes. These changes are largely due to the presence of lens epithelial cells that remain on the natural capsular bag 24 after surgery. These epithelial cells continue to grow and can cause problems. For example, the anterior surface of the natural capsular bag 24 can fibrose and contract over time causing a progressively smaller aperture overtop of the lens. If the entire natural capsular bag 24 becomes fibrotic, and phimosis persists, there can be zonular dehiscence and changes to the effective lens position over time. In addition, about 30% of the time, the posterior surface of the natural capsular bag 24 becomes significantly opacified requiring a YAG laser posterior capsulotomy. The effect of limiting epithelial cell migration and propagation would largely be mediated by the type of material used in forming the PPL-C 10, however hydrophobic acrylic materials tend to be most efficacious of all known and used IOL materials.


Fourth, the PPL-C 10 helps maintain the effective lens position of an IOL 28 implanted into the eye. Precisely matching the preoperative dimensions of the cataract with the PPL-C 10 enhances a physician's ability to predict the ELP of the lens implant. Currently, the ELP of an IOL 28 is estimated based on a number of factors, including the depth of the anterior segment 26, lens thickness, and white to white diameter, among others. However, these measurements are simply used to predict the ELP. The accuracy of the prediction is actually quite low, resulting in only 50% of patients being within a tolerable level of their refractive goal post-cataract surgery. While other dimensions of the eye required for IOL calculation can be measured quite precisely and accurately, the ELP has remained the elusive last great variable to conquer in the quest for highly accurate and predictable IOL calculations for cataract surgery.


The reason for the great variability in the ELP is due to the volumetric difference between the cataract and the IOL. The average thickness of the human cataract at age 65 is approximately 4.5 mm, however this varies from patient to patient. In contrast, an IOL 28 is typically less than 1 mm thick. This volumetric difference allows for pressure differentials between the posterior segment 32 and the anterior segment 26, as well as contraction of the natural capsular bag 24 to shift the final resting position of the IOL 28. The lens thickness will be measured preoperatively and a PPL-C 10 with a corresponding volume and thickness will be implanted. By implanting a PPL-C 10, the volume of the natural capsular bag 24 is effectively held constant. It resists forces that would otherwise shift it and its contents anteriorly or posteriorly. This stability of lens capsule volume will make IOL calculations much more accurate.


Fifth, the PPL-C 10 allows for an intraoperative pseudophakic refraction while still allowing another IOL to be implanted without explanting the original lens. Recently, there have been advances in IOL calculation methodologies that use intraoperative refraction devices, such as the Wavetec ORA and Orange systems, to provide better refractive outcomes. These devices can perform aphakic refractions, pseudophakic refractions, and assist with the alignment of toric IOLs and assist with Limbal Relaxing Incisions. Aphakic refractions do not have the benefit of any lens inside the eye, so ELP is still a variable that this data cannot account for. Pseudophakic refractions can be helpful, but it provides the information only after the IOL has been implanted. If the data shows a different lens would be more beneficial, it would require the physician to explants the lens and implant a different one. Explanting a lens takes time, effort and skill, and can cause damage to the cornea or other structures within the eye. Using a PPL-C 10 with a low power lens incorporated into its posterior surface, e.g., the posterior refractive surface 19, allows a physician to perform a pseudophakic refraction with this refractive surface, and still provides the physician the ability to implant a second lens, e.g., the IOL 28, within the PPL-C 10 that will make up the refractive difference as measured by the intraoperative refraction device, such as the Wavetec ORA.


Sixth, the PPL-C 10 may serve as a means for pharmaceutical delivery. Pharmaceuticals, drugs, medications, such as, for example, slow release medicine pellets, or other substances intended for introduction into the eye may be placed within PPL-C 10 outside of the visual axis 15 in a location that is not subject to sequestration by membrane formation. There is a tremendous amount of research and demand for a slow release implant that would essentially eliminate the need for post cataract surgery eye drops. The PPL-C 10 would be a suitable receptacle for such an implant as the periphery of the interior of the PPL-C provides a location outside of the visual axis 15, in constant contact with the aqueous humor, without risk of becoming encapsulated by scarring, and prevents the implant from damaging natural intraocular structures. Due to the prosthetic material of the PPL-C 10, there would be no risk of membrane formation or encapsulation. Dissolved or suspended pharmaceuticals would not affect the patient's vision and could be introduced directly into the PPL-C 10 during the implantation surgery. Larger pharmaceuticals, such as slow release medicine pellets, may be shaped to mechanically maintain their position with respect to the PPL-C 10. For example, a slow release medicine pellet may be constructed with a generally toroidal shape sized to fit within the PPL-C, while remaining in the peripheral space and not obstructing the visual axis 15.


Seventh, the PPL-C 10 provides physicians with the ability to perform a lens exchange in the future that will have much less risk of damage to the natural capsular bag 24 and zonular apparatus. As stated above, if a PPL-C 10 is placed in the natural capsular bag 24 and a YAG laser posterior capsulotomy has been performed, there is still an adequate barrier for the vitreous in place. In addition, the haptics 30 which hold the IOL 28 in place inside the PPL-C 10 are not prone to scar formation, thus making future lens removal much easier.



FIGS. 5-7 depict a second embodiment of the present invention. In this embodiment, the PPL-C 110 is a substantially discoid shape of approximately 4.5 mm in thickness by 9 mm in diameter. The thickness of the PPL-C 110 is the distance between the anterior surface 114 and posterior surface 116 of the PPL-C 110 along the visual axis 15. The anterior surface 114 contains a circular opening 118 approximately 6 mm in diameter. At least a portion of the inner face 117 of the posterior surface 116 of the PPL-C 110 is made of a refractive surface, e.g. the posterior refractive surface 119. This second embodiment of differs from the first embodiment in that the PPL-C 110 lacks a flange and would therefore not be mechanically fixated or centered on the capsulorhexis. Rather, the volume of the PPL-C 110 relative to the opening of the capsulorhexis would keep the device in place much in the same way current single piece IOLs are folded and placed within the natural capsular bag.


This second embodiment PPL-C 110 sacrifices a measure of stability as compared to the first embodiment PPL-C 10. However, without a flange, this second embodiment is usable for non-femtosecond laser cataract removal, i.e. traditional manual phacoemulsification, and may be particularly useful for surgeons who lack access to a femtosecond laser.


In a third embodiment, the lenticular surface on the posterior aspect of the device would have a plano powered lens. Some extreme myopes would not benefit from a +1D refractive surface as they may be in need of a negative IOL power. For patients with these conditions, a PPL-C may be used with a plano or zero power posterior lenticular surface.


In a fourth embodiment, the PPL-C has a −1D posterior refractive lenticular surface as some extreme axial myopes (about 30 mm and beyond) may require this type of lens.


In a fifth embodiment, the posterior refractive surface 19 is a multifocal lenticular surface rather than a standard monofocal +1D surface, which would aid in presbyopia correction. This multifocal lenticular surface includes, but is not limited to, refractive, diffractive, and zonal multifocal refractive technology. Typically, a multifocal lens would be designed to provide multiple focal points that would range from plano, e.g., 0 diopters, to +3D at the spectacle plane.


In a sixth embodiment, the posterior refractive surface 19 includes a spherical and cylinderic (astigmatic) lenticular surface so as to aid in the correction of pre-existing and surgically induced corneal astigmatism. As most surgeons induce between −0.25 D and −0.50 D of astigmatism with their corneal incisions required for cataract surgery, it would be beneficial even for most patients with spherical corneas to have this neutralized. The diopteric power of the toric correction could increase up to 6 diopters for patients with even higher amounts of astigmatism.


The foregoing detailed description is given primarily for clearness of understanding and no unnecessary limitations are to be understood therefrom for modifications can be made by those skilled in the art upon reading this disclosure and may be made without departing from the spirit of the invention.

Claims
  • 1. A prosthetic implant device for insertion into a natural capsular bag of an eye after removal of a cataract, wherein the prosthetic implant device comprises: an anterior side including an opening;a posterior side; anda deformable sidewall between the anterior side and the posterior side,wherein the prosthetic implant device is configured to mechanically maintain substantially a volume of the natural capsular bag,wherein the prosthetic implant device is configured to self-expand to maintain substantially the volume of the natural capsular bag,wherein the prosthetic implant device is adapted to contain an intraocular lens,wherein the prosthetic implant device has sufficient elasticity to resume a pre-folded shape once positioned in the eye, andwherein the deformable sidewall forms a single continuous wall from the anterior side to the posterior side.
  • 2. The prosthetic implant device of claim 1, wherein the prosthetic implant device comprises a biologically compatible material.
  • 3. The prosthetic implant device of claim 1, wherein the prosthetic implant device comprises an optically clear material.
  • 4. The prosthetic implant device of claim 1, wherein the prosthetic implant device comprises at least one of the following materials: collamer and acrylic.
  • 5. The prosthetic implant device of claim 1, wherein the prosthetic implant device is foldable.
  • 6. The prosthetic implant device of claim 1, wherein the intraocular lens is configured to be placed in physical contact with a peripheral internal surface of the deformable sidewall.
  • 7. The prosthetic implant device of claim 1, the intraocular lens comprises a refractive surface.
  • 8. The prosthetic implant device of claim 1, wherein the intraocular lens includes at least one or more of the following characteristics: concave, convex, spherical, aspheric, wavefront, multifocal diffractive, multifocal refractive, multifocal zonal, accommodative, UV filtering, diffractive chromatic aberration reducing, and astigmatism correcting toric form.
  • 9. The prosthetic implant device of claim 1, wherein a portion of the prosthetic implant device is adapted to lie within the natural capsular bag and is shaped such that an exterior contour of the ophthalmic implant device conforms to a shape of the natural capsular bag.
  • 10. The prosthetic implant device of claim 9, wherein the exterior contour is adapted to mechanically maintain the prosthetic implant device at a specific position and orientation within the eye.
  • 11. The prosthetic implant device of claim 1, wherein the prosthetic implant device is substantially discoid in shape.
  • 12. The prosthetic implant device of claim 1, wherein the prosthetic implant device is approximately the size, shape, and volume of a natural human lens.
  • 13. The prosthetic implant device of claim 1, wherein the opening is configured to be open when the prosthetic implant device is inserted in the eye.
  • 14. The prosthetic implant device of claim 1, wherein the prosthetic implant device comprises a prosthetic barrier separating an anterior segment and posterior segment of the eye.
  • 15. The prosthetic implant device of claim 1, wherein the prosthetic implant device configured to receive pharmaceuticals for delivery to the eye.
  • 16. The prosthetic implant device of claim 1, wherein the prosthetic implant device is configured to enable a future lens exchange of the intraocular lenses.
  • 17. The prosthetic implant device of claim 1, wherein the intraocular lens comprises one or more haptics.
  • 18. The prosthetic implant device of claim 17, wherein the one or more haptics are configured to physically contact a peripheral internal surface of the deformable sidewall.
  • 19. The prosthetic implant device of claim 1, wherein the intraocular lens is between −30 diopters and +30 diopters.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 17/037,271, filed Sep. 29, 2020, which is a continuation of U.S. patent Ser. No. 16/135,806, filed Sep. 19, 2018 and issued as U.S. Pat. No. 10,820,985 on Nov. 3, 2020, which is a continuation of U.S. patent application Ser. No. 14/551,544, filed Nov. 24, 2014 and issued as U.S. Pat. No. 10,136,989 on Nov. 27, 2018, which is a continuation of U.S. patent application Ser. No. 13/402,398, filed Feb. 22, 2012 and issued as U.S. Pat. No. 8,900,300 on Dec. 2, 2014, each of which is incorporated herein by reference in its entirety under 37 C.F.R. § 1.57. Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated by references in their entirety under 37 C.F.R. § 1.57.

US Referenced Citations (358)
Number Name Date Kind
4073014 Poler Feb 1978 A
4373218 Schachar Feb 1983 A
4402579 Poler Sep 1983 A
4423856 Takahashi et al. Jan 1984 A
4435856 L'Esperance Mar 1984 A
4575373 Johnson Mar 1986 A
4585456 Blackmore Apr 1986 A
4629461 Clayman et al. Dec 1986 A
4685921 Peyman Aug 1987 A
4704124 Shearing Nov 1987 A
4731078 Stoy et al. Mar 1988 A
4816031 Pfoff Mar 1989 A
4833890 Kelman May 1989 A
4842601 Smith Jun 1989 A
4888012 Horn et al. Dec 1989 A
4888016 Langerman Dec 1989 A
4892543 Turley Jan 1990 A
4932966 Christie et al. Jun 1990 A
5147395 Willis Sep 1992 A
5171266 Wiley et al. Dec 1992 A
5180390 Drews Jan 1993 A
5203788 Wiley Apr 1993 A
5222981 Werblin Jun 1993 A
5275623 Sarfarazi Jan 1994 A
5326347 Cumming Jul 1994 A
5358520 Patel Oct 1994 A
5522891 Klaas Jun 1996 A
5562731 Cumming Oct 1996 A
5628795 Langerman May 1997 A
5628798 Eggleston et al. May 1997 A
5653751 Samiy et al. Aug 1997 A
5674282 Cumming Oct 1997 A
5676669 Colvard Oct 1997 A
5697973 Peyman et al. Dec 1997 A
5702402 Brady Dec 1997 A
5800533 Eggleston et al. Sep 1998 A
5964802 Anello et al. Oct 1999 A
5968094 Werblin et al. Oct 1999 A
5984962 Anello et al. Nov 1999 A
6015435 Valunin Jan 2000 A
6027531 Tassignon Feb 2000 A
6113633 Portney Sep 2000 A
6117171 Skottun Sep 2000 A
6136026 Israel Oct 2000 A
6143244 Xia et al. Nov 2000 A
6217612 Woods Apr 2001 B1
6235055 Chu May 2001 B1
6280471 Peyman et al. Aug 2001 B1
6299641 Woods Oct 2001 B1
6322589 Cumming Nov 2001 B1
6413276 Werblin Jul 2002 B1
6428574 Valunin Aug 2002 B1
6443985 Woods Sep 2002 B1
6450642 Jethmalani et al. Sep 2002 B1
6454801 Portney Sep 2002 B1
6464725 Skotton Oct 2002 B2
6488708 Sarfarazi Dec 2002 B2
6503276 Lang et al. Jan 2003 B2
6506212 Zhou et al. Jan 2003 B2
6524340 Israel Feb 2003 B2
6533813 Lin et al. Mar 2003 B1
6537281 Portney Mar 2003 B1
6537317 Steinert Mar 2003 B1
6576012 Lang Jun 2003 B2
6596026 Gross Jul 2003 B1
6645246 Weinschenk Nov 2003 B1
6695881 Peng et al. Feb 2004 B2
6721043 Platt et al. Apr 2004 B2
6749634 Hanna Jun 2004 B2
6761737 Zadno-Azizi et al. Jul 2004 B2
6764511 Zadno-Azizi et al. Jul 2004 B2
6786934 Zadno-Azizi et al. Sep 2004 B2
6797004 Brady et al. Sep 2004 B1
6813097 Jethmalani et al. Nov 2004 B2
6818158 Pham et al. Nov 2004 B2
6824266 Jethmalani et al. Nov 2004 B2
6827738 Willis et al. Dec 2004 B2
6846326 Zadno-Azizi et al. Jan 2005 B2
6851804 Jethmalani et al. Feb 2005 B2
6858040 Nguyen et al. Feb 2005 B2
6881225 Okada Apr 2005 B2
6884261 Zadno-Azizi et al. Apr 2005 B2
6884263 Valyunin et al. Apr 2005 B2
6899732 Zadno-Azizi et al. May 2005 B2
6905641 Platt et al. Jun 2005 B2
6917416 Platt et al. Jul 2005 B2
6921416 Khoury Jul 2005 B2
6926736 Peng et al. Aug 2005 B2
6960230 Haefliger Nov 2005 B2
6960231 Tran Nov 2005 B2
6972033 McNicholas Dec 2005 B2
6986900 Yaacobi Jan 2006 B2
7001374 Peyman Feb 2006 B2
7001427 Aharoni et al. Feb 2006 B2
7025783 Brady et al. Apr 2006 B2
7029497 Zhang et al. Apr 2006 B2
7041134 Nguyen et al. May 2006 B2
7074840 Chang et al. Jul 2006 B2
7087080 Zadno-Azizi et al. Aug 2006 B2
7105110 Platt et al. Sep 2006 B2
7118596 Zadno-Azizi et al. Oct 2006 B2
7119894 Platt et al. Oct 2006 B2
7122053 Esch Oct 2006 B2
7125422 Woods Oct 2006 B2
7134755 Jethmalani et al. Nov 2006 B2
7144423 McDonald Dec 2006 B2
7150760 Zhang Dec 2006 B2
7198640 Nguyen Apr 2007 B2
7210783 Jethmalani et al. May 2007 B2
7223288 Zhang et al. May 2007 B2
7226478 Ting et al. Jun 2007 B2
7237893 Chang et al. Jul 2007 B2
7241009 Kornfield et al. Jul 2007 B2
7281795 Sandstedt et al. Oct 2007 B2
7300464 Tran Nov 2007 B2
7414714 Platt et al. Aug 2008 B2
7452362 Zadno-Azizi et al. Nov 2008 B2
7452378 Zadno-Azizi et al. Nov 2008 B2
7462193 Nagamoto Dec 2008 B2
7560499 Jethmalani et al. Jul 2009 B2
7658364 Robinson et al. Feb 2010 B2
7662179 Sarfarazi Feb 2010 B2
7713299 Brady et al. May 2010 B2
7744603 Zadno-Azizi et al. Jun 2010 B2
7744646 Zadno-Azizi et al. Jun 2010 B2
7771471 Dell Aug 2010 B2
7780729 Nguyen et al. Aug 2010 B2
7798644 Jethmalani et al. Sep 2010 B2
7806929 Brown Oct 2010 B2
7811320 Werblin et al. Oct 2010 B2
7837326 Jethmalani et al. Nov 2010 B2
7871437 Hermans et al. Jan 2011 B2
7988285 Sandstedt et al. Aug 2011 B2
7988291 Ianchulev Aug 2011 B2
8025823 Pham et al. Sep 2011 B2
8034107 Stenger Oct 2011 B2
8048155 Shadduck Nov 2011 B2
8052752 Woods et al. Nov 2011 B2
8062361 Nguyen et al. Nov 2011 B2
8088161 Aharoni et al. Jan 2012 B2
8100965 Cumming Jan 2012 B2
8128693 Tran et al. Mar 2012 B2
8162927 Peyman et al. Apr 2012 B2
8187325 Zadno-Azizi et al. May 2012 B2
8197539 Nasiatka et al. Jun 2012 B2
8246679 Nguyen et al. Aug 2012 B2
8273123 Ben Nun Sep 2012 B2
8343216 Brady et al. Jan 2013 B2
8361353 Brait et al. Jan 2013 B2
8398709 Nun et al. Mar 2013 B2
8486142 Bumbalough et al. Jul 2013 B2
8505822 Wang et al. Aug 2013 B2
8506074 Gerbaud Aug 2013 B2
8545556 Woods et al. Oct 2013 B2
8556967 Sarfarazi et al. Oct 2013 B2
8574295 Roholt Nov 2013 B2
8579971 Webb Nov 2013 B2
8585556 Spoeth et al. Nov 2013 B2
8585758 Woods Nov 2013 B2
8608799 Blake et al. Dec 2013 B2
8663235 Tassignon Mar 2014 B2
8728158 Whitsett May 2014 B2
8778022 Blum et al. Jul 2014 B2
8821166 Akura et al. Sep 2014 B2
8834565 Ben Nun Sep 2014 B2
8900300 Wortz Dec 2014 B1
8915588 Blum et al. Dec 2014 B2
8931896 Blum et al. Jan 2015 B2
9005282 Chang et al. Apr 2015 B2
9005283 Nguyen et al. Apr 2015 B2
9039760 Brady et al. May 2015 B2
9072600 Tran Jul 2015 B2
9078744 Van Noy Jul 2015 B2
9095424 Kahook et al. Aug 2015 B2
9119710 Grubbs et al. Sep 2015 B2
9124796 Blum et al. Sep 2015 B2
9125736 Kahook et al. Sep 2015 B2
9149356 Sarfarazi Oct 2015 B2
9173527 Ulrich et al. Nov 2015 B2
9186243 Van Noy Nov 2015 B2
9198752 Woods Dec 2015 B2
9289287 Kahook et al. Mar 2016 B2
9339375 Lee et al. May 2016 B2
9358103 Wortz et al. Jun 2016 B1
9364316 Kahook et al. Jun 2016 B1
9387069 Kahook et al. Jul 2016 B2
9414907 Wortz et al. Aug 2016 B2
9421088 Kahook et al. Aug 2016 B1
9439754 Wortz Sep 2016 B2
9504558 Wortz et al. Nov 2016 B2
9517127 Wortz et al. Dec 2016 B2
9522059 Wortz et al. Dec 2016 B2
9522060 Wortz et al. Dec 2016 B2
9554890 Wortz et al. Jan 2017 B2
9597176 Wortz et al. Mar 2017 B2
9629712 Stenger Apr 2017 B2
9642699 Wortz et al. May 2017 B2
9681946 Kahook et al. Jun 2017 B2
9763771 Wortz et al. Sep 2017 B1
9925037 Wortz et al. Mar 2018 B2
9993336 Wortz et al. Jun 2018 B2
10004594 Wortz et al. Jun 2018 B2
10111746 Wortz et al. Oct 2018 B2
10136989 Wortz et al. Nov 2018 B2
10271945 Wortz et al. Apr 2019 B2
10492903 Wortz et al. Jul 2019 B1
10603162 Wortz et al. Mar 2020 B2
10743983 Wortz et al. Aug 2020 B2
10813745 Wortz Oct 2020 B2
10820985 Wortz Nov 2020 B2
10842615 Wortz et al. Nov 2020 B2
10898315 Wortz et al. Jan 2021 B2
11007050 Wortz May 2021 B1
11013592 Wortz May 2021 B1
11033381 Wortz Jun 2021 B2
11213381 Wortz Jan 2022 B2
11224504 Wortz Jan 2022 B2
20010047204 Zhou et al. Nov 2001 A1
20010051825 Peterson Dec 2001 A1
20020128710 Eggleston Sep 2002 A1
20020143395 Skottun Oct 2002 A1
20020173846 Blake et al. Nov 2002 A1
20030004569 Haefliger Jan 2003 A1
20030050695 Lin et al. Mar 2003 A1
20030090624 Jethmalani et al. May 2003 A1
20030149479 Snyder et al. Aug 2003 A1
20030149480 Shadduck Aug 2003 A1
20030151831 Sandstedt et al. Aug 2003 A1
20030176521 Jethmalani et al. Sep 2003 A1
20030187505 Liao Oct 2003 A1
20040064182 Kelman Apr 2004 A1
20040082993 Woods Apr 2004 A1
20040082995 Woods Apr 2004 A1
20040106993 Portney Jun 2004 A1
20040117011 Aharoni et al. Jun 2004 A1
20040148022 Eggleston Jul 2004 A1
20040158322 Shen et al. Aug 2004 A1
20040167622 Sunalp et al. Aug 2004 A1
20040208910 Ashton et al. Oct 2004 A1
20040254438 Chuck et al. Dec 2004 A1
20050021138 Woods Jan 2005 A1
20050085907 Hanna Apr 2005 A1
20050099597 Sandstedt et al. May 2005 A1
20050107875 Cumming May 2005 A1
20050113911 Peyman May 2005 A1
20050113913 Duvert et al. May 2005 A1
20050137703 Chen Jun 2005 A1
20050154457 Aharoni et al. Jul 2005 A1
20050187623 Tassignon Aug 2005 A1
20050222577 Vaquero Oct 2005 A1
20050234285 Khoury Oct 2005 A1
20050246018 Grubbs et al. Nov 2005 A1
20060027939 Brait et al. Feb 2006 A1
20060047339 Brown Mar 2006 A1
20060064161 Blake Mar 2006 A1
20060095128 Blum et al. May 2006 A1
20060212116 Woods Sep 2006 A1
20060253196 Woods Nov 2006 A1
20060259139 Zadno-Azizi et al. Nov 2006 A1
20060261502 Platt et al. Nov 2006 A1
20070027538 Aharoni et al. Feb 2007 A1
20070027541 Aharoni et al. Feb 2007 A1
20070032868 Woods Feb 2007 A1
20070083261 Colvard Apr 2007 A1
20070093892 MacKool Apr 2007 A1
20070100444 Brady et al. May 2007 A1
20070118216 Pynson May 2007 A1
20070123767 Montegrande et al. May 2007 A1
20070123981 Tassignon May 2007 A1
20070162118 Rozakis et al. Jul 2007 A1
20070213816 Sarfarazi Sep 2007 A1
20070244560 Ossipov et al. Oct 2007 A1
20070260308 Tran Nov 2007 A1
20080086206 Nasiatka et al. Apr 2008 A1
20080097599 Rozakis et al. Apr 2008 A1
20080221676 Coleman et al. Sep 2008 A1
20080300680 Joshua Dec 2008 A1
20090005864 Eggleston Jan 2009 A1
20090182423 Zheng Jul 2009 A1
20100022945 Rodstrom Jan 2010 A1
20100030225 Ianchulev Feb 2010 A1
20100204788 Van Noy Aug 2010 A1
20100211171 Sarfarazi Aug 2010 A1
20100228344 Shadduck Sep 2010 A1
20100280609 Simonov et al. Nov 2010 A1
20110015541 Padrick et al. Jan 2011 A1
20110040378 Werblin Feb 2011 A1
20110153014 Zhang et al. Jun 2011 A1
20110181834 Gerbaud Jul 2011 A1
20110224788 Webb Sep 2011 A1
20110288638 Smiley et al. Nov 2011 A1
20110295367 Cuevas Dec 2011 A1
20110313521 Angelopoulos Dec 2011 A1
20120078363 Lu et al. Mar 2012 A1
20120078364 Stenger Mar 2012 A1
20120179249 Coleman Jul 2012 A1
20120226351 Peyman Sep 2012 A1
20120238857 Wong et al. Sep 2012 A1
20120253458 Geraghty et al. Oct 2012 A1
20130072591 Sandstedt et al. Mar 2013 A1
20130110233 Ghabra May 2013 A1
20130116781 Nun May 2013 A1
20130184815 Roholt Jul 2013 A1
20130190868 Kahook et al. Jul 2013 A1
20130197637 Brait et al. Aug 2013 A1
20130245754 Blum et al. Sep 2013 A1
20130289153 Sandstedt et al. Oct 2013 A1
20130304206 Pallikaris et al. Nov 2013 A1
20130310931 Kahook et al. Nov 2013 A1
20130317458 Kopczynski et al. Nov 2013 A1
20140052246 Kahook et al. Feb 2014 A1
20140067059 Webb Mar 2014 A1
20140172089 Lee et al. Jun 2014 A1
20140228949 Argento et al. Aug 2014 A1
20140343379 Pugh Nov 2014 A1
20140371852 Aharoni et al. Dec 2014 A1
20140379079 Ben Nun Dec 2014 A1
20150061990 Toner et al. Mar 2015 A1
20150088253 Doll et al. Mar 2015 A1
20150100046 Ambati et al. Apr 2015 A1
20150157452 Maliarov et al. Jun 2015 A1
20150182330 Grant Jul 2015 A1
20150223930 Shiuey Aug 2015 A1
20150230981 Kahook et al. Aug 2015 A1
20150238309 Jansen et al. Aug 2015 A1
20150272727 Humayun et al. Oct 2015 A1
20150289970 Akura Oct 2015 A1
20150335420 Blum et al. Nov 2015 A1
20150366660 Martinez et al. Dec 2015 A1
20160000558 Honigsbaum Jan 2016 A1
20160008126 Salahieh et al. Jan 2016 A1
20160030161 Brady et al. Feb 2016 A1
20160030163 Akahoshi Feb 2016 A1
20160058552 Argal et al. Mar 2016 A1
20160058553 Salahieh et al. Mar 2016 A1
20160074154 Woods Mar 2016 A1
20160113760 Conrad Apr 2016 A1
20160113761 Nishi et al. Apr 2016 A1
20160271645 Brady et al. Sep 2016 A1
20160278912 Kahook et al. Sep 2016 A1
20160310263 Akura Oct 2016 A1
20160317287 Silverstrini et al. Nov 2016 A1
20160324629 Sandstedt et al. Nov 2016 A1
20160331519 Kahook et al. Nov 2016 A1
20160339657 Grubbs et al. Nov 2016 A1
20170000602 Sohn et al. Jan 2017 A1
20170020658 Grubbs et al. Jan 2017 A1
20170042667 Collins et al. Feb 2017 A1
20170049560 Cherne Feb 2017 A1
20170119521 Kahook et al. May 2017 A1
20170172732 Lu et al. Jun 2017 A1
20170319332 Kahook et al. Nov 2017 A1
20170348094 Sohn Dec 2017 A1
20190105152 Pallikaris Apr 2019 A1
20190374334 Brady Dec 2019 A1
20200261216 Wortz Aug 2020 A1
20210128295 Wortz May 2021 A1
20210275203 Wortz Sep 2021 A1
Foreign Referenced Citations (66)
Number Date Country
202013009162 Feb 2014 DE
0 337 390 Feb 1993 EP
0 294 039 Jul 1993 EP
0 528 325 Dec 1996 EP
0 732 090 Jun 2002 EP
1 653 886 May 2006 EP
1 499 264 Aug 2006 EP
1 100 411 Nov 2006 EP
1 694 253 Aug 2007 EP
1 852 090 Nov 2007 EP
1 562 521 Dec 2009 EP
1 475 055 Apr 2010 EP
1 933 768 Oct 2010 EP
2 315 559 May 2011 EP
1 438 930 Sep 2011 EP
2 412 337 Feb 2012 EP
1 296 616 May 2012 EP
1 906 881 Aug 2012 EP
2 512 374 Oct 2012 EP
2 851 038 Mar 2015 EP
2 620 130 Jul 2016 EP
2 799 637 Apr 2001 FR
2 804 860 Aug 2001 FR
2 966 340 Apr 2012 FR
S63-89154 Apr 1988 JP
H09-173363 Jul 1997 JP
2005-143886 Jun 2005 JP
2009-285309 Dec 2009 JP
2013-544116 Dec 2013 JP
2017-519221 Jul 2017 JP
WO 98017205 Apr 1998 WO
WO 99024541 May 1999 WO
WO 99062433 Dec 1999 WO
WO 0164136 Sep 2001 WO
WO 02026121 Apr 2002 WO
WO 02071983 Sep 2002 WO
WO 03058296 Jul 2003 WO
WO 05016191 Feb 2005 WO
WO 05094727 Oct 2005 WO
WO 05107649 Nov 2005 WO
WO 06002201 Jan 2006 WO
WO 06050171 May 2006 WO
WO 06124016 Nov 2006 WO
WO 06135572 Dec 2006 WO
WO 07030799 Mar 2007 WO
WO 06015315 Apr 2007 WO
WO 07121296 Oct 2007 WO
WO 10002215 Apr 2010 WO
WO 11163080 Dec 2011 WO
WO 12067994 May 2012 WO
WO 12161749 Nov 2012 WO
WO 13039707 Mar 2013 WO
WO 13112589 Aug 2013 WO
WO 14167425 Oct 2014 WO
WO 14197170 Dec 2014 WO
WO 14201956 Dec 2014 WO
WO 15044235 Apr 2015 WO
WO 15066532 May 2015 WO
WO 15126604 Aug 2015 WO
WO 15198236 Dec 2015 WO
WO 15200056 Dec 2015 WO
WO 16122805 Aug 2016 WO
WO 16187497 Nov 2016 WO
WO 17030582 Feb 2017 WO
WO 17079449 May 2017 WO
WO 17192855 Nov 2017 WO
Non-Patent Literature Citations (18)
Entry
Allergan, “Positive Phase I/II Interim Data of Bimatoprost Sustained-Release Implant for IOP Therapy in Glaucoma”, Nov. 16, 2015, http://www.allergan.com/NEWS/News/Thomson-Reuters/Positive-Phase-I-II-Interim-Data-of-Bimatoprost-Su in 4 pages.
Becker et al., “Accuracy of Lens Power Calculation and Centration of an Aspheric Intraocular Lens”, Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, Oct. 2006, 103(10):873-876. [English Abstract].
Guttman-Krader Cheryl , “Small-aperture optic IOL broadens range of vision”, Article in Ophthalmology Times on Dec. 1, 2014 in 6 pages.
Kleiman et al., “Post-operative Results with Implantation of the Acrysof SA-60 Intraocular lens into the Ciliary Sulcus”, Invest Ophthalmol. Vis Sci. May 2002, 43:E-Abstract 380 in 2 pages.
Kleinmann Guy, “Open-Capsule Device for PCO Prevention”, Power Point Presentation for Hanita Lenses, Oct. 17, 2013 in 20 pages.
Koeppl et al., “Change in IOL position and capsular bag size with an angulated intraocular lens early after cataract surgery”, J Cataract Refractive Surg. Feb. 2005, 31(2):348-353.
Lim et al., “Surgical management of late dislocated lens capsular bag with intraocular lens and endocapsular tension ring”, J Cataract Refractive Surg., Mar. 2006, 32(3):533-535.
Review of Optometry, “Tracking IOP With an IOL”, Sep. 15, 2014 in 1 page.
Wirtitsch et al., “Effect of haptic design on change in axial lens position after cataract surgery”, J Catar Refractive Surg., Jan. 2004, (30)1:45-51.
International Search report and Written Opinion dated May 31, 2013 for Application No. PCT/US2013/026820.
International Preliminary Report on Patentability, dated Aug. 26, 2014, in PCT App. No. PCT/US2013/026820.
Office Action issued in European Application No. 13710641.5, dated Oct. 1, 2015, in 5 pages.
Office Action issued in Japanese Patent Application No. 2014-558790, dated Feb. 3, 2015, in 9 pages.
Notice of Allowance issued in Japanese Patent Application No. 2014-558790, dated Jun. 25, 2015, in 3 pages.
Office Action issued in Japanese Patent Application No. 2015-146248, dated Nov. 28, 2016, in 13 pages.
International Search Report and Written Opinion issued in PCT App. No. PCT/US2015/036263, dated Oct. 7, 2015.
International Preliminary Report on Patentability, dated Dec. 20, 2016, in PCT App. No. PCT/US2015/036263.
International Search Report and Written Opinion issued in PCT Application No. PCT/US2015/065887, dated Apr. 6, 2016.
Related Publications (1)
Number Date Country
20220183816 A1 Jun 2022 US
Continuations (4)
Number Date Country
Parent 17037271 Sep 2020 US
Child 17457360 US
Parent 16135806 Sep 2018 US
Child 17037271 US
Parent 14551544 Nov 2014 US
Child 16135806 US
Parent 13402398 Feb 2012 US
Child 14551544 US